Profit before payment of interest, taxes and amortization: markertherapeutics.com (MRKR)

Marker Therapeutics aims to reduce the production costs of lymphoma therapies, although the clinical trial stage requires colossal expenditures. The absolute operating profit on this chart resolves this dissonance, where the parameter value reaches 0.00, confirming high cash flow volatility. Ultimately, large-scale R&D investments in non-engineered MultiTAA cell products strengthen the company's scientific potential in the fight against blood cancer.

Marker Therapeutics, Inc. (MRKR) Profit before payment of interest, taxes and amortization: for the period 11/23/2025 - 11/15/2026

Summary analytical data breakdowns for Marker Therapeutics (MRKR)

- stock price and consensus target price:

Price Chart Marker Therapeutics|MRKR - Price Target Chart

- company stock exchange capitalization indicators:

Market Value Marker Therapeutics Inc|MRKR - Total Company Value

- business book valuation details:

Net Asset Value per Share Marker Therapeutics|MRKR - Company Book Value|Market-to-Book Ratio markertherapeutics.com|MRKR - Company Total Assets

- debt level and financial liquidity data:

- earnings and market multiples details:

MRKR - Net Profit|Expected Net Profit Marker Therapeutics|MRKR - Price to Earnings Ratio|Future Price to Earnings Multiple markertherapeutics.com|MRKR - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Marker Bio|MRKR - Operating profit before deduction of amortization|Earnings per share for the last four quarters Marker Therapeutics|MRKR - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months markertherapeutics.com|MRKR - Earnings growth in current year|Expected net earnings per share growth next year Marker Therapeutics

- sales and revenue data:

MRKR - Company Revenue|Company Future Revenue Marker Bio|MRKR - P/S Multiple|Forward P/S Multiple Marker Therapeutics Inc

Summary company analytics:MRKR (Marker Therapeutics, Inc.)

This indicator captures the actual cash flow from core operations before taxes and depreciation, allowing investors to assess the business's operational efficiency in real time. Analyzing the EBITDA chart is critical for Marker Therapeutics (MRKR), as it reflects the company's financial stability during the development of affordable cell therapy methods to combat hematological malignancies.

Competitors of Marker Therapeutics (MRKR)